Compass Therapeutics (NASDAQ:CMPX – Get Free Report) is anticipated to release its earnings data before the market opens on ...

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Free Report) has earned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Ratings reports. Two analysts ...

Compass Therapeutics, Inc.’s CMPX share price has dipped by 11.90%, which has investors questioning if this is right time to buy.

In this article, we are going to take a look at where Compass Therapeutics, Inc. (NASDAQ:CMPX) stands against the other ...

BOSTON - Compass Therapeutics, Inc. (NASDAQ: CMPX) shares gained 2.7% after the clinical-stage oncology company reported progress across its pipeline and provided a business update for 2024. While the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Fintel reports that on February 24, 2025, Guggenheim initiated coverage of Compass Therapeutics (NasdaqCM:CMPX) with a Buy recommendation. Analyst Price Forecast Suggests 266.05% Upside As of February ...

Financially, CMPX has a market cap of $423mn, a cash balance of $135mn, and a cash runway of 10-11 quarters, ensuring sufficient funding. The BTC market is small and competitive, with existing ...

Shares of Compass Therapeutics (NASDAQ:CMPX) were up 8% in afternoon trading Monday after Guggenheim initiated coverage of the stock with a buy rating ahead of upcoming data for the company's drug ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings ...